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ABSTRACT
Small interfering RNAs (siRNAs) have revolution-
ized the treatment of liver diseases. However, ro-
bust siRNA delivery to other tissues represents a
major technological need. Conjugating lipids (e.g.
docosanoic acid, DCA) to siRNA supports extra-
hepatic delivery, but tissue accumulation and gene
silencing efficacy are lower than that achieved in
liver by clinical-stage compounds. The chemical
structure of conjugated siRNA may significantly im-
pact in vivo efficacy, particularly in tissues with
lower compound accumulation. Here, we report the
first systematic evaluation of the impact of siRNA
scaffold––i.e. structure, phosphorothioate (PS) con-
tent, linker composition––on DCA-conjugated siRNA
delivery and efficacy in vivo. We found that struc-
tural asymmetry (e.g. 5- or 2-nt overhang) has no
impact on accumulation, but is a principal factor for
enhancing activity in extrahepatic tissues. Similarly,
linker chemistry (cleavable versus stable) altered ac-
tivity, but not accumulation. In contrast, increasing
PS content enhanced accumulation of asymmetric
compounds, but negatively impacted efficacy. Our
findings suggest that siRNA tissue accumulation
does not fully define efficacy, and that the impact
of siRNA chemical structure on activity is driven by
intracellular re-distribution and endosomal escape.
Fine-tuning siRNA chemical structure for optimal ex-
trahepatic efficacy is a critical next step for the pro-
gression of therapeutic RNAi applications beyond
liver.
INTRODUCTION
Small interfering RNA (siRNA)-based therapeutics are rev-
olutionizing human medicine, particularly for liver indica-
tions. Indeed, chemically modified N-acetylgalactosamine
(GalNAc)-conjugated siRNAs demonstrate robust efficacy
in liver (1–3), with a single subcutaneous injection support-
ing a duration of effect of up to 12 months without adverse
events (4–6). However, as of today, clinically efficient siR-
NAs are limited to liver only. To expand therapeutic siRNA
delivery to tissues beyond liver, lipid conjugation strategies
have been explored (7–12).
Recently, we found that docosanoic acid (DCA)-
conjugated siRNAs support functional delivery to a wide
range of tissues, including muscle, heart, fat, adrenal glands
and lung, without causing overt toxicity (13,14). Impor-
tantly, DCA enabled 3- to 9-fold higher siRNA levels in ex-
trahepatic tissues compared to cholesterol, a more widely
used hydrophobic conjugate (13). However, the level of ex-
trahepatic silencing (30–60%) remains significantly lower
than that routinely achieved in the liver (80–90%). Thus,
further optimization of conjugated siRNAs targeting extra-
hepatic tissues is needed.
For conjugate-mediated delivery, full chemical stabiliza-
tion of siRNAs is required (15–17) to prevent rapid degra-
dation during tissue distribution and intracellular relocal-
ization and to enable long duration of effect. In general,
chemical scaffolds that replace every 2′ hydroxyl (18–20),
modify terminal nucleotide linkages (21,22) and stabilize
the 5′ phosphate (23–26) are able to enhance stability, mini-
mize innate immunity and maximize in vivo activity of con-
jugated siRNAs. However, the nature and position of the
chemical modifications within siRNA may significantly im-
pact their degree and duration of effect (17,27). For ex-
ample, the extent of phosphorothioate (PS) modifications,
which have been shown to impact protein binding (28–31),
can significantly alter both in vitro and in vivo siRNA cel-
lular uptake, trafficking and accumulation (21,30). Addi-
tionally, siRNA structure––e.g. asymmetric siRNAs con-
taining a single-stranded overhang––may alter efficacy by
enhancing passive cellular uptake and improving recogni-
tion by the RNA-induced silencing complex (RISC) (15,32–
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35). Finally, the chemical linker connecting the conjugate
to siRNA may influence compound efficacy in vivo, which
was observed with antisense oligonucleotides (ASO) (36).
Thus, fine-tuning the chemical and structural nature of con-
jugated siRNAs may provide an opportunity to enhance
gene silencing in tissues beyond liver. However, the effect
of chemical structure on siRNA distribution and efficacy
in extrahepatic tissues has never been systematically evalu-
ated; and thus, is not fully understood.
Here, we methodically evaluated how altering chemical
structure, PS content and linker chemistry of conjugated
siRNAs affects extrahepatic tissue distribution and activ-
ity in vivo (Figure 1). To this end, we synthesized and de-
livered a panel of diverse DCA-conjugated siRNAs with
asymmetric (5-nucleotide (nt) overhang), conventional (2-
nt overhang) or blunt (no overhang) ends, varying num-
bers of PS modifications, and differing linker chemistries
to mice. We found that, even with similar tissue accumu-
lation, asymmetric and conventional siRNAs induce better
silencing than blunt siRNAs in kidneys, spleen, heart, lung,
muscle and adrenal glands. Using a cleavable linker also en-
hanced silencing activity across tissues. Conversely, increas-
ing PS content was detrimental for functional efficacy in tis-
sues despite being essential for siRNA stability and enhanc-
ing accumulation. Our findings demonstrate that improved
extrahepatic efficacy of siRNAs requires combinatorial op-
timization of conjugate identity, siRNA chemical structure,
PS content and linker chemistry.
MATERIALS AND METHODS
Oligonucleotide synthesis
A MerMade 12 synthesizer was used to synthesize oligonu-
cleotides following standard protocols. DCA-conjugated
sense strands were synthesized at 10 mole scales on
custom synthesized DCA-functionalized controlled pore
glass (CPG) supports (13). Antisense strands were syn-
thesized at 10 mole scales on CPG functionalized with
Unylinker® (ChemGenes, Wilmington, MA, USA). All
phosphoramidites were prepared as 0.15 M solutions in dry
acetonitrile, and coupled using 0.25 M 5-(benzylthio)-1H-
tetrazole (BTT) in acetonitrile as an activator for 250 s.
Trityl groups were removed using 3% dichloroacetic acid
in dichloromethane for 80 s. Unreacted 5′ hydroxyls on the
growing oligonucleotide chain were capped with 16% N-
methylimidazole in tetrahydrofuran (CAP B) and 80:10:10
(v/v/v) tetrahydrofuran:acetic anhydride:2,6-lutidine (CAP
A) for 15 s. Sulfurizations were carried out with 0.1 M
solution of 3-[(dimethylaminomethylene)amino]-3H-1,2,4-
dithiazole-5-thione (DDTT) in acetonitrile for 3 min. Oxi-
dation was performed with 0.02 M iodine in tetrahydrofu-
ran:pyridine:water (70:20:10, v/v/v) for 80 s.
Deprotection and purification of oligonucleotides
Sense strands were cleaved and deprotected using 40% aq.
methylamine at 45◦C for 1 h or ammonia-methylamine
(AMA) at room temperature for 2 h. Antisense strands
were first deprotected with a solution of bromotrimethyl-
silane:pyridine (3:2, v/v) in dichloromethane (5 ml) for (E)-
vinylphosphonate deprotection, then cleaved and depro-
tected with 40% aq. methylamine at 45◦C for 1 h or AMA
at room temperature for 2 h. After drying overnight un-
der vacuum (Speedvac), the resulting oligonucleotide pel-
lets were suspended in water and purified using an Agilent
Prostar System (Agilent, Santa Clara, CA, USA). Sense
strands were purified over a Hamilton HxSil C18 column
in a continuous gradient of sodium acetate: 90% Buffer
A1 (50 mM sodium acetate in 5% acetonitrile) and 10%
Buffer B1 (acetonitrile) to 10% Buffer A1 and 90% Buffer
B1 at a flow rate of 30 ml/min for 18 min at 60◦C. Anti-
sense strands were purified over an ion-exchange column
(GE Source 15Q media) in a continuous gradient of sodium
perchlorate: 100% Buffer A2 (10 mM sodium acetate in
20% acetonitrile) to 60% Buffer A2 and 40% Buffer B2
(1 M sodium perchlorate in 20% acetonitrile) at a flow
rate of 30 ml/min for 30 min at 60◦C. Purified oligonu-
cleotides were desalted by size-exclusion chromatography
and characterized by Liquid Chromatography-Mass Spec-
trometry (LC-MS) analysis on an Agilent 6530 accurate-
mass Q-TOF LC/MS (Agilent technologies, Santa Clara,
CA, USA).
Injection of conjugated siRNAs into mice
Animal experiments were performed in accordance with an-
imal care ethics approval and guidelines of the University of
Massachusetts Medical School Institutional Animal Care
and Use Committee (IACUC, protocol number A-2411).
Six- to seven-week-old female FVB/NJ mice (n = 5 per
group) were injected subcutaneously with DCA-conjugated
siRNA (20 mg/kg), a non-targeting control (Ntc) siRNA
(20 mg/kg) or phosphate-buffered saline (PBS).
Peptide nucleic acid (PNA) hybridization assay
At 1-week post-injection, the amount of siRNA antisense
strand in tissues was determined using a peptide nucleic acid
(PNA) hybridization assay, as described (37,38). Briefly, tis-
sues (15 mg) were lysed in 300 l MasterPure tissue ly-
sis solution (EpiCentre) containing 0.2 mg/ml proteinase
K (Invitrogen). Sodium dodecyl sulphate was precipitated
from lysates by adding 20 l 3 M potassium chloride, and
pelleted by centrifugation at 5000 × g for 15 min. DCA-
conjugated siRNAs in cleared supernatant were hybridized
to a Cy3-labeled PNA probe fully complementary to the
antisense strand (PNABio, Thousand Oaks, CA, USA).
Samples were analyzed by HPLC (Agilent, Santa Clara,
CA, USA) over a DNAPac PA100 anion-exchange col-
umn (Thermo Fisher Scientific). Cy3 fluorescence was mon-
itored and peaks integrated. Final concentrations were as-
certained using calibration curves.
In vivo mRNA silencing experiments
At 1-week post-injection, tissues were collected and stored
in RNAlater (Sigma) at 4◦C overnight. mRNA was then
quantified using the QuantiGene 2.0 Assay (Affymetrix).
Briefly, tissue punches were lysed in 300 l Homogenizing
Buffer (Affymetrix) containing 0.2 mg/ml proteinase K (In-
vitrogen). Diluted lysates and probe sets (mouse Htt, mouse
Ppib, or mouse Hprt) were added to the bDNA capture
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Figure 1. Variation of siRNA chemical structure, PS content and linker chemistry to evaluate the impact of these three major features on tissue distribution
and efficacy in vivo.
plate and signal was amplified and detected as described
by Coles et al. (39). Luminescence was detected on a Tecan
M1000 (Tecan, Morrisville, NC, USA).
Statistical analysis
Data were analyzed using GraphPad Prism 8.1.2 software
(GraphPad Software, Inc., San Diego, CA, USA). For each
independent experiment in mice, the level of silencing was
normalized to the mean of the PBS control group. Data
were analyzed using non-parametric one-way ANOVA with
Dunnett’s test for multiple comparisons, and significance
was calculated relative to PBS controls. T-tests were used
for comparison between two groups.
RESULTS
The presence of a PS-modified 2- or 5-nt overhang does not
alter DCA-siRNA tissue accumulation, but does enhance ex-
trahepatic efficacy
Design of siRNA chemical structures. A wide variety of
siRNA structures, including asymmetric siRNAs with five-
seven nucleobase overhangs (15,33–35), conventional siR-
NAs with two-nucleobase overhangs (17,40), blunt com-
pounds (41) and Dicer substrates (42,43), have been shown
to be active in vitro and in vivo. However, the effect of these
structures on the extrahepatic distribution and efficacy of
siRNAs has not been systematically determined.
To evaluate the effect of siRNA structure on distribu-
tion and efficacy, we selected three different siRNA scaf-
folds (Figure 2A). For all compounds, an alternating 2′-O-
methyl and 2′-fluoro modification pattern with terminal PS
linkage stabilization was used (18,21–22). Moreover, the an-
tisense strand was modified with a 5′-(E)-vinylphosphonate
(E-VP) group that mimics the 5′-phosphate of the antisense
strand to promote recognition by RISC (23,24) and provide
stability against phosphatases and exonucleases (25,26). To
support broad distribution and silencing in a wide range of
tissues––i.e. liver, heart, lung, fat, muscle, adrenal gland and
spleen (13,14)––a docosanoic acid (DCA) conjugate was at-
tached at the 3′-end of the sense strand through two phos-
phodiester bonds between two thymidines (dT-PO linker)
(7,44–45). Finally, all three siRNA variants had the same
20-base antisense strand chemical structure containing 9 PS
modifications.
The only variation in the siRNA scaffold was the length
of the sense strand, which dictated the length of the single-
stranded PS overhang. Specifically, we used a 15-base sense
strand to generate a compound with a 5-nucleotide (nt) PS
overhang (asymmetric siRNA); an 18-base sense strand to
generate a 2-nt PS overhang (conventional siRNA); and a
20-base sense strand to generate a 0-nt PS overhang (blunt
siRNA) (Figure 2A).
siRNA structure has no impact on compound tissue accumu-
lation. To evaluate the effect of siRNA structure on tis-
sue distribution, mice were injected via a single subcuta-
neous (SC) injection with one of the three different siRNA
scaffolds (20 mg/kg). At 1-week post-injection, antisense
strand accumulation was measured in tissues using PNA hy-
bridization assay (37,38). In this study, we limited our focus
on tissues where DCA-conjugated siRNA silencing was pre-
viously observed (13) and thus liver, kidney, spleen, lung,
heart, muscle and fat were selected. For all siRNA scaf-
folds, two siRNA sequences––Huntingtin (Htt) (46) and
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Figure 2. siRNA structure and presence of the PS-modified overhang does not impact tissue distribution and accumulation profiles. (A) Schematic of
siRNA chemical structures used to evaluate the impact of phosphorothioate overhang length on siRNA extrahepatic distribution and efficacy. (B) Bar
graph showing accumulation of DCA-conjugated siRNA targeting Htt (top) or Ppib (bottom) mRNA in liver, kidney, spleen, lung, heart, muscle and
fat. siRNA accumulation measured 1-week after a single subcutaneous injection of DCA-siRNAs (20 mg/kg; n = 5–6 mice per group ± SD) by PNA
hybridization assay. Data analysis: t-test (*P < 0.05). (C) Bar graph showing the tissue accumulation ratio of asymmetric or conventional siRNAs to blunt
siRNA targeting Htt (left) or Ppib (right) mRNA.
Cyclophilin B (Ppib) (47)––were used to evaluate the rela-
tive impact of siRNA nucleobase composition on distribu-
tion profile.
We observed no significant difference in primary and sec-
ondary tissues accumulation profile between the two se-
quences (Figure 2B), indicating that nucleobase composi-
tion has no major impact on DCA-mediated tissue distri-
bution. Contrary to unconjugated compounds (13), DCA-
conjugated siRNAs were quantitatively retained (close to
100% of injected dose), and distributed to a wide range of
tissues, with highest accumulation observed in liver. Sur-
prisingly, the length of the PS overhang had no significant
impact on DCA-mediated distribution across extrahepatic
tissues (Figure 2B and C), except for fat, where blunt (0-nt
overhang) siRNAs accumulated significantly more (2 fold,
P < 0.05) than asymmetric (5-nt overhabg) and conven-
tional siRNAs (2-nt overhang) compounds (Figure 2C).
These findings suggest that tissue accumulation is primar-
ily driven by the conjugate, with minimal contribution from
siRNA sequence and structure.
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siRNA structure significantly impacts efficacy. To evaluate
if similar levels of tissue accumulation translates to simi-
lar silencing efficacy for each siRNA structure, mice were
SC injected with a single dose (n = 5–6 per group, 20
mg/kg) of each DCA-conjugated siRNA variant targeting
either Htt (46) or Ppib (47). Both targets have validated
siRNA sequences available, and are expressed in a wide
range of tissues at different levels (Htt low; Ppib high). Con-
trol mice were treated with either a non-targeting control
(Ntc) siRNA or PBS. At 1-week post-injection, measure-
ments of Htt, Ppib and Hprt (hypoxanthine-guanine phos-
phoribosyl transferase, a housekeeping gene) mRNA levels
were performed in liver, kidney, spleen, lung, heart, adrenal
glands, muscle and fat. Figure 3 shows the silencing efficacy
of each compound in each tissue (compared to PBS, One-
way ANOVA). We then determined whether there were sta-
tistically significant differences in silencing between the dif-
ferent scaffolds, as shown in the Figure 3D heatmap.
Ntc showed no significant reduction in target gene ex-
pression, indicating that the observed silencing is due to
sequence-specific effects (Figure 3). Overall, functional effi-
cacy of DCA-conjugated siRNAs was similar between Htt
and Ppib. For both targets, DCA-conjugated siRNA en-
abled silencing up to 70% in liver and up to 50–60% in heart,
adrenal glands, muscle and fat. However, the exact degree
of silencing differed slightly between the two tested targets,
likely due to differences in cell-type specific expression and
the degree of nuclear retention of each mRNA.
All scaffolds showed significant silencing in liver (∼50–
70%), likely due to the high accumulation in this tissue (Fig-
ure 3A–C). Surprisingly, despite the degree of extrahepatic
accumulation being similar for all siRNA scaffolds (Figure
2B), we observed a significant impact of siRNA structure
on extrahepatic gene silencing. For the blunt structure, si-
lencing efficacy was highest in fat tissue (Figure 3C), corre-
lating to its enhanced accumulation (Figure 2B). However,
blunt siRNAs achieved statistically significant silencing in
only two (out of six) other extrahepatic tissues (lung and
heart when targeting Htt; heart and adrenal when target-
ing Ppib) (Figure 3C). Excluding fat, blunt siRNAs exhib-
ited only 36% max silencing in extrahepatic tissues, much
lower than that of asymmetric (61% max silencing) and con-
ventional (55% max silencing) siRNAs (Figure 3A and B,
respectively). Indeed, asymmetric siRNAs showed signifi-
cantly better silencing (11–59% increases in silencing) com-
pared to the blunt structure in six extrahepatic tissues when
targeting Htt (kidney, spleen, lung, heart, adrenal glands
and muscle), and five tissues when targeting Ppib (kidney,
spleen, lung, adrenal and muscle) (Figure 4). Conventional
siRNAs achieved greater silencing than blunt siRNAs
(12–38% increases in silencing) in spleen, heart, adrenal
glands and muscle (when targeting Htt), and in kidney,
spleen, adrenal glands and muscle (when targeting Ppib,
Figure 4).
Asymmetric siRNA exhibited the best extrahepatic effi-
cacy overall, with silencing observed in all tissues (varying
between 11 and 61%) (Figure 3A). Conventional siRNAs
demonstrated slightly lower (but fairly comparable) activity,
with silencing observed in seven out of eight tissues (vary-
ing between 17 and 55%) (Figure 3B). Asymmetric siRNA
were slightly more potent compared to conventional siRNA
in four of the extrahepatic tissues (when targeting Htt), and
2 extrahepatic tissues (when targeting Ppib, Figure 3D).
When correlating siRNA tissue accumulation and effi-
cacy (Figure 4A), it is immediately clear that the silencing
enhancement observed with asymmetric and conventional
siRNAs versus blunt was not related to changes in accu-
mulation. In general, Ppib targeting siRNAs accumulated
slightly more in all tissues and for all structures than Htt
targeting compounds, but the relative enhancement in effi-
cacy stayed consistent between the two targets. Figure 4B
shows change in silencing versus accumulation of asym-
metric siRNA (left panel) and conventional siRNA (right
panel) relative to blunt siRNA. All analyzed tissues and tar-
gets are plotted in the same graph. This visualization tool
clearly shows (Figure 4B) an overall increase in activity for
overhang-containing compounds in the majority of tissues
(up to minus 50–60%).
Collectively, these results suggest that the presence (rather
than length) of a PS overhang significantly enhances ac-
tivity, possibly by influencing internalization mechanisms
and/or degree of endosomal escape.
PS content impacts DCA-siRNA distribution and efficacy
PS content affects siRNA distribution profile in the context
of conventional siRNAs. For ASO, PS modifications define
relative liver/kidney distribution. Fully PS ASOs preferen-
tially distribute to liver due to tight serum protein binding.
Decreasing the PS content on ASOs reduces serum binding
affinity, shifting accumulation to kidney proximal epithelia,
which retain a fraction of ASOs during clearance (21,48–
49).
To determine whether the extent of PS modifications im-
pacts extrahepatic distribution of siRNAs, we compared
the distribution profile of DCA-conjugated siRNA with
eight terminal PS modifications (two at each termini, ‘low
PS’) versus 13 PS modifications (‘high PS’) in the context
of conventional (2-nt overhang) and blunt (0-nt overhang)
siRNA structures (Figure 5A). Levels of antisense strand
accumulation were measured in liver, kidney, spleen, lung,
heart, muscle and fat 1 week after SC injection of DCA-
conjugated siRNA targeting either Htt or Ppib (Figure 5B).
In the context of blunt DCA-conjugated siRNA, change
in PS content had minimal impact on tissue distribution
profiles (Figure 5). However, for conventional siRNAs, the
change in PS content significantly affected tissue accumu-
lation. Specifically, low-PS compounds showed lower accu-
mulation in most tissues––∼3- to 3.5-fold for liver, ∼1.5-
to 3-fold for kidneys, ∼2- to 4-fold for spleen, ∼2-fold for
lung, ∼0- to 2-fold for heart and muscle and ∼0- to 3-fold
for fat (Figure 5C). These observations can be explained, in
part, by the lower stability of ‘low PS’ overhang compared
to the ‘high PS’ overhang in conventional siRNAs. Collec-
tively, these results suggest that PS modifications likely pro-
mote siRNA accumulation and retention in tissues by pre-
venting siRNA degradation and altering clearance kinetics.
High PS content has a negative impact on siRNA activity.
To evaluate if accumulation correlates with silencing, tar-
get mRNA levels were measured in tissues after injection
of low PS and high PS blunt and conventional siRNAs
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Figure 3. Presence of 5- or 2-nt PS-modified overhang enhances extrahepatic activity of DCA-conjugated siRNAs. Percent silencing in liver, kidney,
spleen, lung, heart, adrenal glands, muscle and fat after subcutaneous injection of asymmetric (A), conventional (B) or blunt (C) DCA-conjugated siRNA
targeting Htt (left panel) or Ppib (right panel) mRNA (n = 5–6 mice per group, 20 mg/kg). mRNA levels were measured using QuantiGene® (Affymetrix),
normalized to a housekeeping gene, Hprt (Hypoxanthine-guanine phosphoribosyl transferase) and presented as percent of PBS control (mean ± SD). Data
analysis: One-way ANOVA with Dunnett test for multiple comparisons (****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.1). (D) Heat map indicating
the degree of statistically significant differences observed between silencing of asymmetric (5-nt overhang), convention (2-nt overhang) and blunt (0-nt
overhang) siRNA scaffolds in various tissues after SC injection of DCA-conjugated siRNA targeting Htt or Ppib mRNA (n = 5–6 mice per group, 20
mg/kg). Data analysis: t-test. Presence of the overhang rather than length of it has a profound impact on observed enhancement in activity.
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Figure 4. siRNA structure does not impact tissue accumulation but dramatically affects efficacy where asymmetric and conventional siNRAs induce the
best silencing. (A) Graph correlating siRNA tissue distribution and efficacy in tissues for asymmetric, conventional and blunt siRNAs targeting Htt and
Ppib. (B) Graph showing differences between mRNA level expression of asymmetric (left panel) or conventional (right panel) to blunt siRNAs for all tissues.
All analyzed tissues and both gene targets are plotted in the same graph. Negative differences indicate a better induction of silencing with asymmetric or
conventional siRNAs compared to blunt compounds.
scaffolds targeting Htt and Ppib. The silencing efficiency of
each compound in each tissue (compared to PBS, One-way
ANOVA) is shown in Figure 6.
Suprisingly, despite of the enhancement in tissue accu-
mulation observed with high PS conventional siRNAs, the
increase in PS content have overall negative impact on activ-
ity (Figure 6). For conventional siRNAs, there were minor
increases in silencing in fat and spleen (15 and 30%, respec-
tively) with high PS compounds, but only observed for Htt
and not Ppib targeting mRNA. At contrary, the clear neg-
ative impact of increase in PS context on efficacy and re-
versed correlation to accumulation can be observed in liver
(Figure 6A). Despite an approximately 3-fold increase in ac-
cumulation with high PS compounds (52–65 pmol/mg for
high PS siRNAs vs 14–29 pmol/mg for low PS siRNAs, Fig-
ure 5), the level of observed liver silencing was reduced from
73 to 47% for Htt (P < 0.01) and from 22 to 11% for Ppib
(P < 0.01) (Figure 6A). When correlating siRNA tissue ac-
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article/48/14/7665/5872468 by U
niversity of M
assachusetts M
edical School user on 30 Septem
ber 2020
7672 Nucleic Acids Research, 2020, Vol. 48, No. 14
Figure 5. Increase in PS content enhances DCA-siRNA tissue accumulation in a context of overhang containing structures. (A) Schematic of siRNA
scaffolds and PS content variation. (B) Bar graph showing accumulation of high-PS and low-PS DCA-conjugated siRNA targeting Htt (top) or Ppib
(bottom) mRNA in liver, kidney, spleen, lung, heart, muscle and fat. siRNA accumulation measured 1-week after a single subcutaneous injection of DCA-
siRNA (20 mg/kg, n = 5–6 mice per group ± SD) by PNA hybridization assay. Data analysis: t-test (***P < 0.001, **P < 0.01, *P < 0.1). (C) Bar graph
showing the tissue accumulation ratio of High PS (13 PS) siRNA to Low PS (8 PS) siRNA targeting Htt (left) or Ppib (right) mRNA.
cumulation and efficacy (Figure 7A), it is stricking that for
conventional siRNAs (pink and red dots, Figure 7A) even
if high PS variants accumulated more in 12 tissues out of 14
compared to low PS siRNAs, high PS compounds induced
statistically significant better silencing in only two tissues
out of 14 (fat and spleen when targeting Htt) (Figures 6A
and 7B). Collectively, these results suggest that an increase
in PS content enhances conventional siRNA stability to in-
crease tissue accumulation, but has a significant, negative
impact on observed functional activity.
The negative impact of increased PS content on silenc-
ing was even more pronounced in the context of blunt siR-
NAs. Indeed, low PS blunt siRNA induced better silencing
(17–30% increases in silencing) than their high PS coun-
terparts for both targets in five out of eight tissues (Fig-
ure 6B). The effect was particularly pronounced in adrenal
glands, where high PS siRNAs induced minimal to no si-
lencing, and low PS compounds showed >55% reduction
in both Htt and Ppib expression.The correlation between
siRNA tissue accumulation and efficacy, clearly shows that
for blunt structures (light and dark purple dots, Figure 7A),
the number of PS did not significantly impact acumulation
levels but affected activity where low PS siRNAs (light pur-
ple dots, Figure 7A) induced better silencing than high PS
compounds (dark purple dots, Figure 7A). The differences
between target mRNA levels of high PS siRNAs (Figure
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Figure 6. Increase in PS content negatively impacts siRNA functional efficacy in the majority of tissues. Percent silencing in liver, kidney, spleen, lung,
heart, adrenal glands, muscle and fat after subcutaneous injection of high-PS and low-PS. (A) Conventional siRNAs or (B) blunt siRNAs targeting Htt
(left panel) or Ppib (right panel) mRNA (n = 5–6 mice per group, 20 mg/kg). mRNA levels were measured using QuantiGene® (Affymetrix), normalized
to a housekeeping gene, Hprt (Hypoxanthine-guanine phosphoribosyl transferase) and presented as percent of PBS (phosphate buffered saline) control
(mean ± SD). Data analysis: t-test (****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.1).
7B, right panel) to low PS compounds (all tissues and tar-
gets plotted in the same graph) results in positive remaining
mRNA expression (up to plus 50%) for the majority of tis-
sues, indicating that low PS siRNAs were more potent than
high PSvariants. These results suggest that, for blunt siR-
NAs with similar stability and distribution, a large number
of PS modifications may alter protein binding inside the cell
to impact siRNA trafficking, endosomal escape and the de-
gree of functional silencing (27–29,50).
The linker chemical composition has a strong impact on
DCA-siRNA efficacy in vivo
A variety of linkers––e.g. triethyleneglycol (TEG) (15),
disulfide (51) and carbon chain (13)––have been used for
conjugated siRNAs and ASOs. Moreover, the introduction
of a cleavable phosphodiester bond between the conjugate
and the oligonucleotide has been shown to improve liver
silencing of cholesterol-conjugated ASOs (36). However,
there has not been a systematic evaluation of the impact of
conjugated siRNA linker chemistry on extrahepatic activity
and distribution in vivo.
In all experiments described thus far (Figures 1–7), siR-
NAs were connected to the DCA conjugate through two
phosphodiester bonds between two thymidines (dT-PO).
The phosphodiester DNA has limited in vivo stability, suf-
ficient to support initial tissue distribution, but quickly de-
graded upon cellular uptake (52). To evaluate the impact of
linker stability on DCA-siRNA tissue accumulation, asym-
metric (5-nt overhang), conventional (2-nt overhang) and
blunt (0-nt overhang) siRNAs were synthesized with either
a cleavable dT-PO linker or a stable carbon (St) linker (Fig-
ure 8A).
As expected, the nature of the linker had no significant
impact on tissue distribution and accumulation profiles for
any siRNA chemical structure (Figure 8B and C), indicat-
ing that dT-PO had sufficient serum stability to allow DCA-
driven distribution. By contrast, the chemical composition
of the linker did have a profound impact on tissue silenc-
ing levels (Figure 9). Specifically, the presence of a cleav-
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Figure 7. High PS content leads to a decrease of siRNA efficacy. (A) Graph correlating siRNA tissue distribution and efficacy in tissues for conventional
high PS and low PS siRNAs and for blunt high PS and low PS siRNAs targeting Htt (upper panel) and Ppib (lower panel). (B) Graph showing differences
between mRNA level expression of conventional high PS (left panel) or blunt high PS (right panel) to the corresponding low PS content variants. All
analyzed tissues and both gene targets are plotted in the same graph. Positive differences indicate a better induction of silencing with low PS siRNAs
compared to high PS compounds.
able linker significantly improved Htt mRNA silencing in
spleen (by 23%, P < 0.001), heart (by 14%, P < 0.001),
adrenal glands (by 21%, P < 0.001) and fat (by 21%, P <
0.1); and significantly improved Ppib mRNA silencing in
liver (by 24%, P < 0.01), kidney (by 20%, P < 0.1), lung (by
22%, P < 0.1), heart (by 25%, P < 0.0001) and fat (by 14%,
P < 0.1) (Figure 9). The correlation between siRNA tis-
sue accumulation and efficacy (Figure 10A) shows distinctly
that the nature of the linker (dT-PO versus St) did not sig-
nificantly impact siRNA tissue distribution (x-axis, Figure
10A) but had a dramatic effect on efficacy (y-axis, Figure
10A). DCA dT-PO linked siRNAs induced better silencing
than DCA St linked compounds for both targets and in all
tissues (except in spleen when targeting Ppib where silenc-
ing was similar with both compounds). The differences be-
tween target mRNA levels of DCA dT-PO siRNAs to DCA
St compounds results in negative remaining mRNA expres-
sion (up to −30%) for the majority of tissues and both tar-
gets (Figure 10B), indicating that the presence of a dT-PO
linker enhanced siRNA efficacy.
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Figure 8. The presence of a cleavable linker between the conjugate and the siRNA does not impact siRNA tissue distribution and accumulation profile.
(A) Schematic of siRNA chemical structures to evaluate the impact dT-PO versus stable carbon (St) linker on distribution. (B) Bar graph showing strand
accumulation of asymmetric (upper), conventional (middle) or blunt (bottom) DCA-conjugated siRNA with dT-PO or stable carbon (St) linker in liver,
kidney, spleen, lung, heart, muscle and fat. siRNA accumulation measured 1-week after a single subcutaneous injection of DCA-siRNA (20 mg/kg, n =
5–6 mice per group ± SD) by PNA hybridization assay. Data analysis: t-test (*P < 0.1). (C) Bar graph showing the tissue accumulation ratio of asymmetric,
conventional and blunt dT-PO linked siRNAs to the corresponding variants St linked siRNAs.
These results suggest that the use of a cleavable linker like
dT-PO promotes silencing in tissues.
DISCUSSION
Conjugation of oligonucleotides to a variety of chemical
entities allows for modulation of bioavailability, tissues ex-
posure and, in some cases, cell-type specific delivery (7–
8,11,53). The recent approval of a fully chemically stabilized
GalNAc siRNA, Givosiran, demonstrates the immense po-
tential of conjugated siRNAs to treat genetic diseases (54).
While a trivalent GalNAc allows specific delivery to hepato-
cytes (1–3,55), lipid conjugation enables functional delivery
to a range of tissues beyond liver (13,14). Among lipophilic
conjugates impacting oligonucleotide bioavailability, tis-
sue distribution, kinetics of clearance and safety (10,13–
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Figure 9. The presence of a cleavable linker enhances DCA-conjugated siRNA silencing in multiple tissues. Percent silencing of Htt (upper panel) and Ppib
(bottom panel) in liver, kidney, spleen, lung, heart, adrenal glands, muscle and fat after subcutaneous injection of asymmetric DCA-conjugated siRNA
with either dT-PO or stable carbon (St) linker into FVB/N mice (20 mg/kg, n = 6 per group). One-week post-injection, tissues were collected, and mRNA
levels were measured using QuantiGene® (Affymetrix), normalized to a housekeeping gene, Hprt (Hypoxanthine-guanine phosphoribosyl transferase),
and presented as percent of PBS control (mean ± SD). Data analysis: t test (****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.1).
14,37,56–57), we identified DCA as a conjugate that sup-
ports widespread extrahepatic distribution (13,14). How-
ever, DCA-siRNA accumulation and degree of silencing in
extrahepatic tissues is less than what is generally observed
for GalNAc conjugates in liver. Indeed, liver naturally ac-
cumulates drugs, including siRNAs, because it is a primary
filtering tissue with high blood flow volumes and discontin-
ued fenestrated epithelia (58), and thus represents a unique
and highly favorable tissue for any drug targeting. To deliver
compounds to other tissues, further optimization of con-
jugated siRNAs is needed. Here, we uncover the interplay
between siRNA structure, chemical composition, and con-
jugate, and how it affects productive extrahepatic silencing.
Such findings will pave the way toward using these classes
of molecules for future therapeutic applications.
PS-modified oligonucleotides enhance protein
binding and cellular uptake in vitro (28,30); and
thus, are a primary factor defining oligonucleotide
pharmacokinetics/dynamics (21,48,59). Yet, the impact
of structural context (e.g. single- versus double-stranded;
nature of conjugate) in which PS modifications are added
can influence PS-induced protein interactions (60). In the
context of a DCA conjugate, we found that the presence of
a 5-nt or 2-nt PS overhang in asymmetric and conventional
siRNAs (respectively) had no measurable effect on tissue
accumulation profiles. This is likely because DCA, a highly
hydrophobic moiety, binds serum protein so tightly (14)
that the relative contribution of PS becomes less significant
(9–10,13–14,57). Despite having no impact on overall
tissue accumulation, the presence of the PS-modified
single-stranded region did impact activity. Asymmetric
siRNAs (5-nt overhang) induced statistically significant
silencing in all tissues tested (16 out of 16), while blunt
siRNA with an identical guide strand were active in only
50% of tissues. Structure variation (asymmetric versus
blunt) had minimal impact on selected sequence activity
in vitro (15), but data presented here are limited to only
two targets. Therefore, it is possible that other target
sequences––i.e. those selected to optimally perform in a
blunt structure––might generate different results. Further-
more, presence of the overhang could potentially enhance
PAZ domain interactions and RISC loading (61–63);
however, as the two chemical structures have very similar
in vitro activity (15), this explanation is unlikely. Because
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article/48/14/7665/5872468 by U
niversity of M
assachusetts M
edical School user on 30 Septem
ber 2020
Nucleic Acids Research, 2020, Vol. 48, No. 14 7677
Figure 10. The linker chemistry does not impact tissue accumulation but dramatically affects efficacy where a cleavable linker induces the best silencing. (A)
Graph correlating siRNA tissue distribution and efficacy in tissues for asymmetric siRNAs having a dT-PO linker and a stable carbon (St) linker targeting
Htt and Ppib. (B) Graph showing differences between mRNA level expression of compounds having a dT-PO linker to siRNAs with a stable carbon (St)
linker. All analyzed tissues and both gene targets are plotted in the same graph. Negative differences indicate a better induction of silencing with DCA
dT-PO linked siRNAs compared to DCA stable carbon (St) linked compounds.
the structures exhibit almost identical tissue accumulation,
the observed functional differences are more likely due to
the impact of the PS tail on intracellular localization (28),
trafficking (29) and the degree of endosomal escape, which
may be a rate limiting step for oligonucleotide activity
(58). Interestingly, the length of the overhang had less of
an impact on activity, with the 5-nt overhang inducing
just slightly better silencing in ∼30% of tissues compared
to 2-nt overhang siRNA. It is possible that the single-
stranded PS region in both siRNAs is sufficient to mimic
the behavior of ASOs; and thus, both alter trafficking and
support efficient silencing (32–35). Collectively, there is a
disconnect between level of accumulation and functional
efficacy (previously observed with a range of different
lipid conjugated siRNAs (13)), which indicates that both
siRNA structural context and conjugate entity contribute
to the intracellular behavior and cumulatively effect
activity.
In addition to structural context, the extent of PS modi-
fications on an oligonucleotide can influence their effect on
stability (64), serum protein binding (21,31,48–49), cellular
receptor binding (65), cellular trafficking (28) and nuclear
localization (27–29). The resulting impact of PS content on
distribution and efficacy of ASOs is well known, but the im-
pact on extrahepatic distribution of conjugated siRNAs is
less clear. Here, we found that decreasing PS content dimin-
ished tissue accumulation of asymmetric and conventional
siRNAs––likely due to a decrease in stability of the single-
stranded overhang. Accumulation of blunt compounds was
unaffected because these compounds (no PS overhang) rely
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Figure 11. Optimized design of lipid conjugated siRNAs for enhancing extrahepatic silencing.
solely on the conjugate to define tissue accumulation. Sur-
prisingly, an increase in PS content negatively impacted si-
lencing for all structural contexts, but particularly for blunt
compounds. It is possible that siRNAs with high-PS con-
tent bind too tightly or to a large variety of proteins inside
the cells, which may alter trafficking, endosomal escape and
reduce a fraction of compounds available for RISC loading
(28–29,50). The exact mechanism requires further investi-
gation, but our results suggest that unnecessary increases
in PS content can be detrimental. Therefore, optimizing a
specific balance between phosphodiester and phosphoroth-
ioate (PO/PS) content will be crucial for lipid-conjugated
siRNAs to achieve maximum silencing in extrahepatic tis-
sues. Indeed, optimization of PO/PS content for tricyclo-
DNA ASOs (in Duchenne Muscular Dystrophy models)
(66), and for oligonucleotides in the central nervous system
has already been done, and is now a widely used strategy
to achieve optimal efficacy, stability, safety (67). Another
strategy for improving extrahepatic gene silencing would be
to replace PS moieties with other chemical entities that sta-
bilize siRNA, reduce cellular protein binding, and maintain
the ability to be recognized by RISC and induce RNAi.
Until now, the relative contribution of linker chemistry
on conjugated-siRNA in vivo efficacy was largely unknown,
partially because linkers have often been considered an in-
ert part of the chemical architecture. However, our findings
demonstrate that, in the context of DCA-siRNAs, the use of
a cleavable linker (dT-PO) had a profound impact on degree
of silencing. We previously found that dT-PO is the simplest
synthetic variant of a cleavable linker and, compared to
mono-dT and rU linkers, has an optimal range of stability
(unpublished data). Indeed, dT-PO (cleavable) and stable
carbon (non-cleavable)-linker DCA siRNAs showed simi-
lar tissue accumulation profile confirming that dT-PO was
stable enough in serum during the early stages of compound
clearance. However, dT-PO significantly increased activity
in several tissues, likely due to its cleavage inside the cells for
enhanced siRNA endosomal escape. The positive effect of a
cleavable linker on endosomal escape and efficacy has been
observed for cholesterol-conjugated ASOs (∼35% increase
in activity) (36), and for GalNAc-ASOs (Reversir) used to
inhibit siRNA activity in liver (68). Although other clinical
GalNAc compounds, such as Inclisiran, do not have a cleav-
able linker and are highly active, the use of a cleavable linker
might be of higher functional significance in the context of
lipid-conjugated siRNAs. For instance, after internalizion
via endocytosis (30), lipid conjugates may be particularly
susceptible to becoming membrane bound, limiting siRNA
cytosol release. A cleavable linker may help overcome this
issue. Overall, dT-PO is easy to synthesize, does not require
special precursors, is non-toxic and is biodegradable; how-
ever, further work should more systematically evaluate di-
verse linker chemistries on siRNA in vivo activity.
Although our findings highlight the importance of op-
timizing chemical structure, there are many other modi-
fications on siRNA that may influence extrahepatic effi-
cacy. For instance, we used an alternating 2′-O-methyl and
2′-fluoro chemical modification pattern (first described by
Allerson et al.) to enable conjugate-mediated siRNA deliv-
ery in vivo (18). While this modification pattern is highly
efficient overall, Crooke et al. demonstrated that 2′-fluoro
modifications within ASOs increase protein binding inside
cells, leading to decreased silencing and increased ASO toxi-
city (69,70). Therefore, additional optimization of this mod-
ification pattern might profoundly impact siRNA potency
and duration of effect in vivo (17); and thus, should be con-
sidered for enhancing extrahepatic silencing. Currently, fur-
ther investigations are in progress to evaluate whether the
optimized design of alternative 2′-O-methyl and 2′-fluoro
compounds described here will be applicable to more OMe-
rich siRNAs.
In summary, our data clearly demonstrate that the
oligonucleotide chemical scaffold and architecture are prin-
cipal factors to consider for optimizing the extrahepatic ac-
tivity of siRNAs. Engineering strategies that alter struc-
tural asymmetry (e.g. 5- or 2-nt overhang versus blunt end)
and linker chemistry (cleavable versus non-cleavable) can be
used to fine-tune siRNA activity in kidney, spleen, heart,
lung, muscle and adrenal gland without impacting tissue
distribution. Moreover, engineering strategies that carefully
balance PS versus PO content can be used to optimize
siRNA stability without compromising functional efficacy
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in tissues. Overall, siRNA designs with an overhang, cleav-
able linker and minimal PS content (Figure 11) should
support enhanced extrahepatic silencing. Our findings will
guide the future design of conjugated siRNAs with optimal
therapeutic profiles.
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